Development of pthaladyn-based dynamin I-selective inhibitors for treatment of epilepsy

开发用于治疗癫痫的基于 pthaladyn 的动力 I 选择性抑制剂

• 批准号: nhmrc : 1017063
• 负责人: A/Pr Megan Chircop
• 金额: $ 37.63万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-pthaladyn-based-treatment-epilepsy/109824
• 关键词: Development; pthaladyn; based; dynamin; selective

About 1% of the World�s population suffers from epilepsy; 30% fail to respond to anti-epileptic drugs (AED). Current AED development pathways have changed little in the past 20 years with the majority of current AEDs dampening the release of crucial chemical signals 24/7. Our new drugs, which inhibit a protein called dynamin, are only recruited at the onset of a seizure. Our approach will significantly enhance the day to day lives of those afflicted by epilepsy.

世界上大约1%的人口患有癫痫; 30%的人对抗癫痫药物（AED）没有反应。在过去的20年里，目前的AED开发途径几乎没有变化，大多数目前的AED都抑制了关键化学信号的释放。我们的新药物，抑制一种叫做发动蛋白的蛋白质，只在癫痫发作时被招募。我们的方法将显著改善癫痫患者的日常生活。